According to the latest "China diagnostic reagent Market report 2013-2015" released by China Market Research Reports, domestic diagnostic reagent companies are gradually breaking the monopoly of foreign brands.

With the deepening of China's medical reform, people's increasing awareness of health and the improvement of detection technology, the Chinese market will further accelerate the expansion.

In China, in vitro diagnostic reagents include biochemical diagnostic reagents, immunodiagnostic reagents, molecular diagnostic reagents and blood diagnostic reagents.

In 2012, China's biochemical and immunological diagnostic agents reached the highest market share of 70%, which was determined by domestic medical demand.

However, the Chinese economy and the government's medical expenditure are still maintained at a low level, which has a great impact on the consumption of medical diagnosis.

Demand for routine testing is expected to peak in China over the next three years.

In China, advances in diagnostic technology and increasing high-end consumers will drive the market demand for molecular diagnostic reagents and other related reagents.

Demand for biochemical and immunological diagnostic agents is forecast to fall to 60% by 2015.

By virtue of high cost performance and local advantages, Chinese diagnostic reagent companies will soon break the monopoly of foreign brands.

However, foreign companies still hold 30-40% of the market share in China, while showing significant technological advantages in the middle and high-end sectors, as well as a monopoly on the integrated platform of "instruments and reagents".